Stereotaxis (STXS) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citizens | Maintained | Market Outperform | $3.00 from $4.00 | Aug 27, 2026 |
| TD Cowen | Maintained | Buy | $3.00 from $5.00 | Aug 12, 2026 |
| Piper Sandler | Maintained | Overweight | $3.50 from $4.00 | May 13, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $4.00 | Dec 16, 2025 |
| Roth Capital | Maintained | Buy | $4.00 | Nov 12, 2025 |
| Roth Capital | Maintained | Buy | $4.00 | Nov 5, 2025 |
| Roth MKM | Maintained | Buy | $5.00 | Mar 5, 2024 |
| Lake Street | Maintained | Buy | $4.00 from $3.00 | Mar 5, 2024 |
| Roth MKM | Initiated Coverage | Buy | $5.00 | Jan 10, 2024 |
Frequently asked questions
Is STXS a buy, sell, or hold?
Analysts covering Stereotaxis currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on STXS?
On Aug 27, 2026, Citizens maintained Stereotaxis at Market Outperform with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.